Hypertrophic cardiomyopathy (HCM) is an uncommon disease with significant consequences. Since the 1950s, major strides in understanding its etiology and pathogenesis have led to improved ...

Hypertrophic cardiomyopathy (HCM) was first described in the late 1950s as a disease typified by substantial thickening of the myocardium, particularly the left ventricular wall, with no overt cause.

Hypertrophic cardiomyopathy, or HCM, is a genetic disease in which the heart muscle grows thicker than normal. You might think of the term “big-hearted” to connote something good, says Dr ...

Background: Symptoms are among the most important factors impacting quality of life (QOL) in hypertrophic cardiomyopathy (HCM) patients, and reflect a poor prognosis. Whether emotional stress can ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.